RINVOQ Outperforms HUMIRA in Head-to-Head Rheumatoid Arthritis Study

AbbVie announced on October 20, 2025, that RINVOQ® (upadacitinib), their newer oral arthritis medication, has demonstrated clear superiority over HUMIRA® (adalimumab), the company’s former bestselling injectable biologic drug, in a head-to-head clinical trial involving rheumatoid arthritis patients who had failed previous TNF inhibitor treatments. The Phase 3b/4 SELECT-SWITCH study met its primary endpoint, showing a statistically significant higher proportion of patients treated with RINVOQ achieved low disease activity compared to those on HUMIRA.

Key Findings From the Trial
In this pivotal trial involving adults with moderate to severe rheumatoid arthritis, 43.3% of patients taking RINVOQ reached low disease activity as measured by DAS28-CRP ≤3.2 by week 12. This compared favorably to only 22.4% of patients receiving HUMIRA, more than doubling the rate of improvement. Furthermore, 28.4% of RINVOQ patients achieved remission, a key secondary endpoint, versus 14.5% with HUMIRA, both outcomes reaching statistical significance without new safety concerns identified. These results highlight RINVOQ’s effectiveness in a population that had previously not responded well to first-line tumor necrosis factor (TNF) inhibitors.

Expert Commentary
Dr. Jonathan Silverberg, Professor of Dermatology and Clinical Research Director at George Washington University, who was not involved in this study, notes, “RINVOQ’s oral mechanism targeting Janus kinase (JAK) enzymes offers a promising alternative for patients struggling with biologics like HUMIRA. The superior rates of remission and low disease activity represent a meaningful advancement in managing rheumatoid arthritis.” Experts emphasize the importance of personalized treatment, as medication tolerance and side effect profiles vary.

Background on Treatments
HUMIRA, a TNF inhibitor administered via biweekly injection, has been a cornerstone of autoimmune disease therapy worldwide since its FDA approval in 2002. It reduces inflammation by blocking the pro-inflammatory cytokine TNF. However, its patent expiration and the entrance of biosimilars in 2023 have impacted sales and prompted the development of newer agents.

RINVOQ is an oral JAK inhibitor that interrupts intracellular signaling pathways responsible for immune activation and inflammation. It has been gaining traction as it may act faster and improve patient adherence by avoiding injections. The SELECT-SWITCH study directly compared RINVOQ 15 mg once daily with HUMIRA 40 mg biweekly, providing clear head-to-head data on their efficacy.

Implications for Public Health and Clinical Practice
These findings suggest that RINVOQ could become a preferred treatment option for rheumatoid arthritis patients who do not respond adequately to TNF inhibitors. The oral administration route, coupled with superior clinical outcomes, may improve patient quality of life and adherence. It also provides clinicians an evidence-based alternative when switching therapies.

Potential Limitations and Safety Considerations
While the efficacy signals are strong, safety profiles differ between the two drugs. HUMIRA carries risks of infections and injection site reactions, whereas JAK inhibitors like RINVOQ may increase risks of cardiovascular events, blood clots, and certain cancers, leading to FDA black box warnings. Long-term studies continuing to monitor safety endpoints are crucial for fully understanding the benefit-risk balance.

Patients with pre-existing cardiovascular conditions or cancer history should discuss treatment options thoroughly with their healthcare providers. The study’s 12-week timeframe provides important but interim results; ongoing data will elucidate long-term remission sustainability and safety.

Conclusion
AbbVie’s SELECT-SWITCH trial provides robust, peer-reviewed evidence supporting RINVOQ’s superiority over HUMIRA in achieving low disease activity and remission in rheumatoid arthritis patients who failed initial TNF inhibitor therapy. This positions RINVOQ as a compelling option for personalized immune-mediated disease management, backed by rigorous clinical data and expert opinion.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References